This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm.
I am proud to announce that I have been asked to lecture to my fellow attorneys at the upcoming American Association for Justice’s (AAJ) seminar “Handling the Pradaxa Claim” on April 11 in Baltimore, MD. I will educate my colleagues on the inadequacy of the Pradaxa labels and warnings.
A little background on Pradaxa- Approved by the FDA in October 2010 to prevent strokes in patients with atrial fibrillation, Pradaxa was the first blood thinner to compete with the longtime treatment of warfarin (brand names Coumadin and Jantoven). From the very first day on the market, troubling reports linking Pradaxa to serious risks that were not communicated to patients flooded the FDA and foreign regulatory bodies.
I firmly believe that manufacturer Boehringer Ingelheim GmbH rushed Pradaxa through clinical trials and the FDA approval process in order to beat two similar drugs to the market, thereby capturing (and subsequently placing at risk) as many consumers as possible.
The Pradaxa case is one of the strongest pharma cases to come about in a long while. The main issues with Pradaxa I see are 4-fold:  1. Hiding the extreme bleeding risk with Pradaxa which is uncurable, 2. pushing Pradaxa on patients who were not adequately studied in the clinical trials (i.e., patients over 75 years of age of low body weight), 3. only studying the highest dose of Pradaxa and that studying being inadequate, 4. and monitoring instructions which were woefully minimized at the expense of patient safety.
The Michael Brady Lynch Firm will be taking the lead in representing Pradaxa victims nationwide. I look forward to seeing my colleagues on April 11 at the American Association for Justice’s (AAJ) upcoming seminar “Handling the Pradaxa Claim”.
If you have experienced internal bleeding / hemorrhaging, stroke, heart attack or have lost a loved one after Pradaxa use, please contact me for a free, no-obligation review of your case.
About the Firm: The Michael Brady Lynch Firm is a trial firm with a focus on pharmaceutical mass tort cases involving SSRI and Anti-Seizure Medication Birth Defects such as Lexapro, Zoloft, Effexor, Prozac, Celexa, Paxil, Depakote and Topamax, as well as Actos Bladder Cancer and Fosamax Femur Fractures, and medical device cases including DePuy Hip and Trans-Vaginal Mesh cases. Contact us today if you or someone you know has experienced side effects involving these products.